NCT04290546 2026-02-27CIML NK Cell in Head & Neck CancerDana-Farber Cancer InstitutePhase 1 Completed11 enrolled
NCT03690986 2025-07-23VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck CancerEmory UniversityPhase 1 Recruiting50 enrolled
NCT02812524 2025-03-10Ipilimumab for Head and Neck Cancer PatientsProvidence Health & ServicesPhase 1 Active not recruiting18 enrolled
NCT01935921 2023-06-15Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck CancerNational Cancer Institute (NCI)Phase 1 Completed19 enrolled
NCT01986426 2018-10-03LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or PembrolizumabLytix Biopharma ASPhase 1 Completed80 enrolled
NCT03098160 2017-10-30Immunotherapy Study of Evofosfamide in Combination With IpilimumabThreshold PharmaceuticalsPhase 1 Unknown69 enrolled